Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions
- PMID: 29924418
- DOI: 10.1002/jbmr.3523
Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions
Abstract
The purpose of this work was to evaluate systemic glucocorticoid exposure and fracture among patients with newly-diagnosed inflammatory and immune-modulated conditions. Using administrative data, inception cohorts of rheumatoid arthritis (RA), asthma/chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), multiple sclerosis (MS), lupus, and sarcoidosis patients age 18 to 64 years with benefits coverage ≥12 months before diagnosis (January 1, 2005 to December 31, 2012) were followed to clinical fracture, cancer diagnosis, or December 31, 2012. Glucocorticoid users were new to therapy. Fracture incidence rates (IRs) per 1000 person-years were stratified by prednisone equivalent doses. Cox's proportional hazards models assessed risk by daily and cumulative dose, and by time since discontinuation, adjusted for baseline characteristics. Most patients (72% of 403,337) had glucocorticoid exposure; 52% were under age 50. IR (95% confidence interval [CI]) of any osteoporotic fracture was elevated at doses <5 mg/day (IR 9.33; 95% CI, 7.29 to 11.77) versus 0 mg/day (IR 4.87 (95% CI, 4.72 to 5.02). Fracture rates were elevated at doses <5 mg/day in patients <50 years and those ≥50 years. In both age groups, fracture risk increased with increasing cumulative exposure, being approximately 2.5-fold higher at cumulative dose ≥5400 mg compared to <675 mg. At ≥5400 mg, IR values were 5.69 (95% CI, 4.32 to 7.35) in patients <50 years and 17.10 (95% CI, 14.97 to 19.46) in older patients. Fracture risk decreased significantly within months following glucocorticoid discontinuation. In patients with a variety of inflammatory conditions, fracture risk increased at doses as low as <5 mg/day. Risk increased with increasing cumulative exposure and decreased soon following glucocorticoid discontinuation. Trends were similar between patients older and younger than 50 years. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.
Keywords: FRACTURE; GLUCOCORTICOIDS; HEALTH SERVICES RESEARCH; OSTEOPOROSIS; RHEUMATOID ARTHRITIS.
© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.
Similar articles
-
Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink.Rheumatology (Oxford). 2022 Apr 11;61(4):1448-1458. doi: 10.1093/rheumatology/keab548. Rheumatology (Oxford). 2022. PMID: 34255815 Free PMC article.
-
Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.Osteoporos Int. 2016 Nov;27(11):3239-3249. doi: 10.1007/s00198-016-3646-z. Epub 2016 Jun 8. Osteoporos Int. 2016. PMID: 27273113
-
Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis.Osteoporos Int. 2017 Oct;28(10):2859-2866. doi: 10.1007/s00198-017-4115-z. Epub 2017 Jun 21. Osteoporos Int. 2017. PMID: 28638981 Free PMC article.
-
Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.Osteoporos Int. 2016 May;27(5):1709-18. doi: 10.1007/s00198-015-3455-9. Epub 2015 Dec 22. Osteoporos Int. 2016. PMID: 26694595 Review.
-
[The effects of glucocorticoid on bone architecture and strength].Clin Calcium. 2013 Jul;23(7):993-9. Clin Calcium. 2013. PMID: 23811587 Review. Japanese.
Cited by
-
Risk Variants in or Near ZBTB40 AND NFATC1 Increase the Risk of Both IBD and Adverse Bone Health Outcomes Highlighting Common Genetic Underpinnings Across Both Diseases.Inflamm Bowel Dis. 2023 Jun 1;29(6):938-945. doi: 10.1093/ibd/izac273. Inflamm Bowel Dis. 2023. PMID: 36680554 Free PMC article.
-
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice.Ther Adv Musculoskelet Dis. 2019 Sep 20;11:1759720X19876468. doi: 10.1177/1759720X19876468. eCollection 2019. Ther Adv Musculoskelet Dis. 2019. PMID: 31565078 Free PMC article. Review.
-
Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink.Rheumatology (Oxford). 2022 Apr 11;61(4):1448-1458. doi: 10.1093/rheumatology/keab548. Rheumatology (Oxford). 2022. PMID: 34255815 Free PMC article.
-
Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users.SAGE Open Med. 2024 Mar 20;12:20503121241235056. doi: 10.1177/20503121241235056. eCollection 2024. SAGE Open Med. 2024. PMID: 38516640 Free PMC article.
-
Risk factors for glucocorticoid induced osteoporosis in young adults.Front Endocrinol (Lausanne). 2025 Jul 11;16:1528962. doi: 10.3389/fendo.2025.1528962. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40717802 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical